The mechanism of action of this drug in the treatment of chronic hepatitis B or in enhancing the responsiveness of the immune system has not been fully identified. In several different in vitro tests, this drug induced T-cell maturation in peripheral blood lymphocytes after mitogen activation, increased secretion of various lymphokines such as alpha, gamma interferon, interleukin 2, and interleukin 3 produced by T-cells after activation of various antigens or mitogens and increased the level of lymphokine receptors on T-cells. It also enhances mixed allogeneic and autologous human lymphocyte responses through activation of T4 helper cells. Thymopeptide alpha 1 may affect the recruitment of NK precursor cells that become more cytotoxic after exposure to interferon. In vivo, thymosin α1 potentiated the increased secretion of interleukin 2, and the increased expression of interleukin 2 receptor, by mouse lymphocytes after activation by cutinoglobulin A.

Guidance:

This drug should not be administered intramuscularly or intravenously. It should be dissolved in the 1.0 mL of water for injection that comes with the box and then immediately injected intradermally.　　Chronic Hepatitis BThe recommended dose of this drug for the treatment of chronic hepatitis B is 1.6 mg per injection, subcutaneously, twice weekly, with two doses approximately 3-4 days apart. Treatment should be given for 6 consecutive months (52 injections) without interruption. If this drug is used in combination with interferon alpha, the dosage and precautions in the prescribing information for interferon alpha should be referred to, and clinical experience with the combination has shown that when the two drugs are used on the same day, the drug is usually given in the morning and the interferon in the evening. As a Vaccine Booster in Immunocompromised PatientsThis drug is used as a viral vaccine booster at the recommended dose of 1.6 mg subcutaneously twice weekly, 3-4 days apart, and the course of therapy should continue for 4 weeks (****8 doses), with the first dose given immediately after the vaccine. Failure.